F. F. Casanueva, M. E. Molitch, J. A. Schlechte, R. Abs, V. Bonert, M. D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L. G. Sobrinho, J. A. Wass and A. Giustina, “Guidelines of the Pituitary Society for the Diagnosis and Management of Prolactinomas,” Clinical Endocrinology (Oxford), Vol. 65, No. 2, 2006, pp. 265-273.

has been cited by the following article:

• TITLE: Combined Treatment with Buserelin+Cabergoline in Patient with Prostate Cancer and Pituitary Macroprolactinoma

  AUTHORS: Gervain Mihály, Vörös Erika, Molnár Andor, Karcsú-Kis Gyöngyi, László Ferenc, László A. Ferenc

  KEYWORDS: Prostate cancer, Prolactinoma, Buserelin; Cabergoline

  JOURNAL NAME: Journal of Cancer Therapy, Vol.1 No.4, December 31, 2010

  ABSTRACT: Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specific antigen levels had decreased dramatically after 3 months of treatment. After 2 years of buserelin administration, the hormonal state was examined. Serum estradiol, testosterone, DHEA, DHEAS, FSH and LH levels proved to be suppressed, but the serum PRL concentration was extremely high (3 365 mIU/l). The pituitary MRI revealed a macroadenoma. The patient was treated with the dopamine agonist cabergoline, together with buserelin. After 9 months of this combined treatment, the prostate-specific antigen and testosterone levels were very low; the serum estradiol, DHEA, DHEAS, FSH and LH concentrations remained suppressed. The serum PRL level fell dramatically to 6.95 mIU/l, and a significant reduction in tumor size was observed on MRI. In conclusion: Combined buserelin + cabergoline treatment proved a highly successful procedure to cure this patient with prostate carcinoma and subsequent pituitary macroprolactinoma.